JPRN-jRCT2051220022进行中（未招募）1 期
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination With Other Anti-Cancer Therapy in Subjects With Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)
Kaneda Hirokazu0 个研究点目标入组 180 人开始时间: 2022年5月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 99age old（—）
- 性别
- All
入选标准
- •1. Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures
- •2. Age >= 18 years old (or legal adult within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed
- •3. Pathologically confirmed squamous cell lung carcinoma
- •4. Disease that is unresectable, locally advanced or metastatic (not amenable to curative therapy)
- •5. Participants must have archived tumor tissue sample (formalin fixed, paraffin embedded [FFPE] sample [FFPE of excisional, or core needle]) taken within last 5 years or be willing to undergo pre-treatment tumor biopsy (excisional, or core needle) for tissue prior to enrollment
- •6. Participant must have progressed on, or recurred after at least 1 prior systemic therapy (Part 1 and 2 only) or at least 2 prior systemic therapies (Part 3 only) for locally advanced and unresectable or metastatic disease. Prior treatment must include aplatinum-based doublet chemotherapy and checkpoint inhibitor for advanced or metastatic disease, either given as one line of therapy or as individual lines of therapy, unless the participant has a medical contraindication to one of the required therapies (which must be documented in the electronic case report form [eCRF]). Additionally, if the participant's tumor was previously identified as having a driver mutation (according to local standard of care or guidelines, e.g., Kirsten rat sarcoma [KRAS] G12C, neurotrophic tyrosine receptor kinase [NTRK]), which has an approved therapy for which the participant is eligible and available, the participant must have received the approved therapy in a prior line of treatment.
- •7. For Part 4, participants may not have received prior systemic therapy for their locally advanced and unresectable or metastatic disease. For Part 4, participants who received peri-operative systemic therapy are eligible if that adjuvant/neoadjuvant therapy was completed at least 12 months prior to diagnosis of locally advanced and unresectable or metastatic disease.
- •8. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria
- •9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •10 Adequate organ function as determined per protocol
- •11. Part 2, 3 and 4 only: FGFR2b overexpression as determined by centrally performed immunohistochemistry (IHC) testing
排除标准
- •1. Mixed small-cell lung cancer or mixed non-small cell lung cancer (NSCLC) histology
- •2. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease
- •3. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures at a frequency greater than monthly
- •4. Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction < 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure >160mmHg or diastolic >100 mm Hg despite optimal treatment (measured following European Society for Hypertension/European Society of Cardiology [ESH/ESC] 2013 guidelines; Section 11.11), uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease, Fridericia's correction formula (QTc) >= 470
- •5. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing
- •6. Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations, keratitis, or keratoconus, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer
- •7. Part 1 and Part 2: participants that experienced toxicity or hypersensitivity requiring discontinuation of prior docetaxel treatment
- •8. Part 1 only: participants that had disease progression on prior therapy with docetaxel
- •9. Part 2 only: participants have received prior docetaxel in unresectable or metastatic setting (including participants who received prior docetaxel in first line for metastatic disease, but not including participants who received prior docetaxel neoadjuvantly or adjuvantly and did not progress within 6 months of end of therapy)
- •10. Prior treatment with any selective inhibitor of the fibroblast growth factor-fibroblast growth factor receptor (FGF-FGFR) pathway
研究者
相似试验
进行中（未招募）
1 期
A Study of Tarlatamab in Participants With Neuroendocrine Prostate Cancer (DeLLpro-300)JPRN-jRCT2031210415Tagashira Shuzo60
撤回
不适用
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaKahler's diseaseplasma cell myelomaRelapsed or Refractory Multiple Myeloma10018865NL-OMON46679Amgen3
已完成
不适用
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancerneuro-endocriene prostaatkankerNeuroendocrine Prostate Cancer10036958Prostate CancerNL-OMON51934Amgen3
招募中
1 期
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis BChronic Hepatitis BACTRN12617000235303Gilead Sciences, Inc.60
进行中（未招募）
1 期
A safety and efficacy study of the drug BGB-290 in combination with Temozolomide (TMZ) in patients with ovarian, breast, prostate, lung and stomach cancer.ocally Advanced or Metastatic Solid Tumors (ovarian cancer, triple negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and gastric cancer)EUCTR2017-001553-14-GBBeiGene USA, Inc.250